Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the first patient enrolled at Yale School of Medicine [1][2] - The trial will assess the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy in reducing alcohol cravings and consumption [2] - The U.S. substance use disorder treatment market was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, highlighting significant market potential for effective AUD treatments [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Clinical Trial Details - Eligible participants for the trial include individuals aged 18 to 60, either heavy binge drinkers or those diagnosed with AUD, who express a desire to reduce or stop drinking [3] - The trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, with additional sites under evaluation [3]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a European patent application for a combination treatment targeting cocaine addiction [1][4] - The patent application is based on preclinical trial results showing that Clearmind's MEAI significantly reduces cocaine-induced craving in animal models [2] - Further research indicates that MEAI specifically targets drug-related compulsions without impairing responses to natural rewards, suggesting a focused mechanism of action [3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, and autism [5] - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder, holding a portfolio of 19 patent families and 31 granted patents [6]

Core Insights - Clearmind Medicine Inc. has announced the publication of a European patent application, strengthening its global intellectual property position and focusing on addiction treatment [1][2] Intellectual Property - The patent EP 4531826 covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines for treating cocaine addiction [2] - The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [7] Research and Development - Preclinical trials led by Professor Gal Yadid at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-induced cravings in animals [3] - Further studies showed that MEAI reduced cocaine-seeking behavior without impairing responses to natural rewards, indicating a targeted effect on drug-related compulsions [4] Strategic Collaboration - The patent application is part of an ongoing collaboration with SciSparc Ltd. to explore the combined potential of MEAI and PEA-based technologies for treating central nervous system disorders [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems, including substance use disorders [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. leading to the filing of a new international patent application for a treatment targeting anorexia, bulimia, and other eating disorders [1][2] Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4] Collaboration Details - The patent application involves the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide (PEA), aiming to address neurobiological and psychological factors associated with eating disorders [2] Industry Context - Eating disorders are serious mental health conditions affecting up to 70 million people globally, with a prevalence increase from 3.4% to 7.8% between 2000 and 2018 [3] - These disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders [3] Clearmind Medicine Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a proprietary treatment targeting anorexia, bulimia, and other eating disorders, highlighting its commitment to developing innovative therapies for under-treated mental health conditions [1][4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant health issues, including eating disorders and alcohol use disorder [5]. - The company currently holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [6]. Treatment Development - The new patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA), targeting the neurobiological and psychological factors associated with eating disorders [2]. - The company aims to provide new treatment options for individuals struggling with eating disorders through the therapeutic potential of 3-MMC and PEA [4]. Industry Context - Eating disorders are serious mental health conditions that significantly impact health, emotions, and daily functioning, with up to 70 million people affected globally [3]. - The prevalence of eating disorders increased from 3.4% to 7.8% between 2000 and 2018, indicating a growing public health concern [3].

Core Viewpoint - Clearmind Medicine Inc. has initiated its U.S. clinical trial for its psychedelic-derived treatment CMND-100 aimed at addressing Alcohol Use Disorder (AUD), marking a significant step in the development of innovative therapies for this under-treated health issue [1][3]. Group 1: Clinical Trial Details - The clinical trial site at Yale School of Medicine's Department of Psychiatry has been activated, with patient enrollment set to begin [1]. - The trial will be led by Dr. Anahita Bassir Nia, M.D., and will also take place at Johns Hopkins University School of Medicine and the IMCA Center in Israel [2]. Group 2: Company Overview and Objectives - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health problems, including AUD [4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. is hosting a live webinar titled "Gazing Through the Crystal Ball" on May 21, 2025, focusing on the evolving landscape of psychedelic science and business amid changing FDA policies and political climates [1] - The company is a clinical-stage biotech firm dedicated to developing psychedelic-derived therapeutics to address significant under-treated health issues, particularly Alcohol Use Disorder (AUD) [7] Event Details - The webinar will feature a panel of experts, including Rick Doblin, PhD, a pioneer in psychedelic-assisted therapy; Robin Carhart-Harris, PhD, known for his work in psychedelic neuroscience; and Dr. Adi Zuloff-Shani, CEO of Clearmind, who is leading the development of CMND-100 for AUD [2][3][4] - The discussion will be moderated by Shannon Smadella, a recognized advocate in the psychedelic space [6] Company Overview - Clearmind's primary objective is to research and develop psychedelic-based compounds for commercialization as regulated medicines, foods, or supplements [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [8]

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discuss ...

Core Insights - Clearmind Medicine Inc. has received a Notice of Allowance for a patent related to its MEAI treatment for binge behavior, enhancing its intellectual property protection and portfolio [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] - The recent patent allowance strengthens the company's position in the psychedelic therapeutics space and supports the development of its MEAI program [2][3]

Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly Alcohol Use Disorder (AUD) [1][7] - The company has a proprietary drug candidate, CMND-100, which is based on MEAI and aims to provide a novel treatment approach for AUD by modulating reward mechanisms associated with addictive behavior [4] Clinical Trial Initiation - Clearmind has initiated its Phase I/IIa clinical trial for CMND-100 at Johns Hopkins University School of Medicine, marking a significant milestone towards FDA approval [1][3] - The trial will also take place at Yale School of Medicine and IMCA Center in Israel, indicating a strong foundation for evaluating the clinical potential of CMND-100 [2][3] Study Objectives - The clinical trial is designed to assess the safety, tolerability, and pharmacokinetics of CMND-100 in individuals diagnosed with AUD, along with preliminary efficacy evaluations to examine its potential in reducing alcohol cravings and consumption [3] Market Context - Alcohol Use Disorder is a major global health challenge, affecting approximately 400 million people aged 15 and older, with 209 million experiencing alcohol dependence [6] - The disorder contributes to 2.6 million deaths annually, accounting for 4.7% of all global deaths, highlighting the urgent need for innovative therapeutic solutions [6] Regulatory and Intellectual Property - Clearmind aims to commercialize its psychedelic-based compounds as regulated medicines, foods, or supplements, and currently holds a portfolio of nineteen patent families with 31 granted patents [7][8]